^
Association details:
| Biomarker: | EGFR mutation + CCND1 expression + CDKN2A deletion |
|---|---|
| Cancer: | Non Small Cell Lung Cancer |
| Drug: | Tagrisso (osimertinib) (EGFR inhibitor) |
| Direction: | Resistant |
Evidence:
Source:
Title:
Intrinsic Resistance to Osimertinib in EGFR Mutated NSCLC Cell Lines Induced by Alteration in Cell-Cycle Regulators
Published date:
10/19/2023
Excerpt:
...we retrospectively reviewed osimertinib outcomes in a group of 32 patients with advanced EGFR-mutated NSCLC treated with first-line osimertinib who were assessed for Cyclin D1 and p16 immunohistochemistry….Among Cyclin D1-positive patients, p16- patients had a significantly lower overall response rate compared with p16+ patients (61% vs 100%, respectively, p = 0.030).
DOI:
https://doi.org/10.1007/s11523-023-01005-0
